Brief: Lava Therapeutics Presents Preclinical Data On Its Gammabody™ T Cell Engager Platform At 21St Annual Peptalk Conference
18/01/2022 13:49
Jan 18 (Reuters) - LAVA Therapeutics NV LVTX.O :
* LAVA THERAPEUTICS PRESENTS PRECLINICAL DATA ON ITS
GAMMABODY™ T
CELL ENGAGER PLATFORM AT 21ST ANNUAL PEPTALK CONFERENCE
Source text for Eikon: ID:nGNX4C251z
Further company coverage: LVTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LAVA Therapeutics NV
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 07:29 PM
Brief: Xoma Royalty Announces Closing Of Transactions To Acquire Lava Therapeutics N.V.
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM